SENORESNSESenores Pharmaceuticals LimitedMediumNeutral
Announced Mon, 2 Jun · 13:57 IST

Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on June 02, 2025.

Board & Shareholder Meetings View source PDF

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Senores Pharmaceuticals' Board of Directors, at a meeting held on June 2, 2025, appointed Sharp & Tannan Associates, Chartered Accountants (Firm Registration No. 109983W) as the Internal Auditor of the Company for the financial year 2025-26. The appointment was made on the recommendation of the Audit Committee. Sharp & Tannan Associates is a well-established firm founded in 1934, headquartered in Mumbai, with nine partners and decades of experience in internal audit, risk-based auditing, and consulting. The Board meeting commenced at 12:15 PM and concluded at 1:40 PM. The disclosure was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Likely market impact

This is a routine governance and regulatory compliance matter. Engaging a reputed, long-standing audit firm like Sharp & Tannan Associates strengthens internal controls and governance, but is unlikely to have any direct impact on the stock price or shareholder value.